Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 17 (1), 105

The Effectiveness of Creatine Treatment for Parkinson's Disease: An Updated Meta-Analysis of Randomized Controlled Trials

Affiliations
Meta-Analysis

The Effectiveness of Creatine Treatment for Parkinson's Disease: An Updated Meta-Analysis of Randomized Controlled Trials

Jia-Jie Mo et al. BMC Neurol.

Abstract

Background: The effectiveness of creatine in treating Parkinson's disease (PD) has not been conclusively determined. Therefore, we performed a meta-analysis to address this issue.

Methods: The Cochrane Central Register of Controlled Trials, PUBMED, EMBASE, and other databases were searched, and outcomes measured by the Total Unified Parkinson's Disease Rating Scale (UPDRS) and the Schwab & England Scale were analyzed.

Results: Five randomized controlled trials (RCTs) were selected, and 1339 participants were included in the analysis. There were no significant differences between the control and treatment groups in the total, mental, activities of daily living (ADL), or motor UPDRS scores, but an improvement in Schwab & England Scale scores was observed.

Conclusions: Creatine has no observed benefit in PD patients, although more correlated studies are still needed.

Keywords: Creatine; Meta-analysis; Mitochondrial dysfunction; Parkinson’s disease.

Figures

Fig. 1
Fig. 1
Assessing the risk of bias of the included studies. a A summary of the authors’ evaluation of the risk of bias criteria for each included study; (b) A graph of the authors’ evaluation of each risk of bias criterion presented as percentages across all included studies Flow chart with inclusion criteria to select studies for this meta-analysis
Fig. 2
Fig. 2
Assessing the risk of bias of the included studies. (a) A summary of the authors’ evaluation of the risk of bias criteria for each included study; (b) A graph of the authors’ evaluation of each risk of bias criterion presented as percentages across all included studies
Fig. 3
Fig. 3
The effect of creatine treatment versus placebo. (a) Change in Total UPDRS scores from baseline; (b) Change in UPDRS Mental scores; (c) Change in UPDRS ADL scores; (d) Change in UPDRS Motor scores; (e) Change in Schwab & England Scale scores

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

References

    1. Lee A, Gilbert RM. Epidemiology of Parkinson disease. Neurol Clin. 2016;34(4):955–965. doi: 10.1016/j.ncl.2016.06.012. - DOI - PubMed
    1. Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, et al. Caffeine and progression of Parkinson disease: a deleterious interaction with Creatine. Clin Neuropharmacol. 2015;38(5):163–169. doi: 10.1097/WNF.0000000000000102. - DOI - PMC - PubMed
    1. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60(8):1234–1240. doi: 10.1212/01.WNL.0000058760.13152.1A. - DOI - PubMed
    1. Comi C, Magistrelli L, Oggioni GD, Carecchio M, Fleetwood T, Cantello R, et al. Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. Parkinsonism Relat Disord. 2014;20(12):1329–1334. doi: 10.1016/j.parkreldis.2014.10.010. - DOI - PubMed
    1. Lewitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology. 2004;63(2):23–31. doi: 10.1212/WNL.63.7_suppl_2.S23. - DOI - PubMed

Publication types

Feedback